1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  06:52 2022-07-06 am EDT
3.460 EUR   -1.56%
06/13Nanoform Chief of Business Operations Gonçalo Andrade steps down
AQ
06/13Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations
CI
06/13Nanoform Finland Plc - Manager's transactions - Jeanne Thoma
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform Finland Plc - Manager's transactions - Niklas Sandler

04/12/2022 | 12:06pm EDT

Company release

Nanoform Finland Plc

April 12, 2022

07:05 p.m. Finnish time / 06:05 p.m. Swedish time

Nanoform Finland Plc - Manager's transactions - Niklas Sandler

Helsinki, Finland - Manager's transaction related to Nanoform Finland Plc's other senior manager Niklas Sandler's share subscription with stock options from option program 2/2019:

Person subject to the notification requirement

Name: Sandler, Niklas

Position: Other senior manager

Issuer: Nanoform Finland Plc

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 743700JJO2NU8LBS1592_20220412162005_5

____________________________________________

Transaction date: 2022-04-12

Venue not applicable

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 30000 Unit price: 1.10 EUR

Aggregated transactions

(1): Volume: 30000 Volume weighted average price: 1.10 EUR

For further information, please contact:

Peter Hänninen

General Counsel

peter.hanninen@nanoform.com

+358 50 353 040

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com

https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---niklas-sandler,c3545439

https://mb.cision.com/Main/18905/3545439/1563601.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
06/13Nanoform Chief of Business Operations Gonçalo Andrade steps down
AQ
06/13Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations
CI
06/13Nanoform Finland Plc - Manager's transactions - Jeanne Thoma
AQ
06/13Nanoform Finland Plc - Manager's transactions - Albert Hæggström
AQ
06/13Nanoform Finland Plc - Manager's transactions - Mads Laustsen
AQ
06/06Share subscriptions based on Nanoform Finland Plc's stock options 1-2/2019 and 1/2020
AQ
06/06The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key..
AQ
06/06Nanoform Finland Plc - Manager's transactions - Miguel Calado
AQ
06/02NANOFORM FINLAND OYJ : Plc – Manager's transactions – Niklas Sandler
PU
06/02Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
More news
Financials
Sales 2022 7,00 M 7,17 M 7,17 M
Net income 2022 -18,7 M -19,2 M -19,2 M
Net cash 2022 74,4 M 76,2 M 76,2 M
P/E ratio 2022 -14,1x
Yield 2022 -
Capitalization 275 M 282 M 282 M
EV / Sales 2022 28,7x
EV / Sales 2023 11,0x
Nbr of Employees 130
Free-Float 74,7%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,52 €
Average target price 8,88 €
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonçalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-46.58%282
JOHNSON & JOHNSON4.94%468 758
ELI LILLY AND COMPANY17.55%294 514
PFIZER, INC.-11.41%289 747
ABBVIE INC.13.69%272 011
ROCHE HOLDING AG-15.85%269 131